Citations

Clear

1575 citation(s) found for "Im, Gene".

Clinical Use of a 16S Ribosomal RNA Gene-Based Sanger and/or Next Generation Sequencing Assay to Test Preoperative Synovial Fluid for Periprosthetic Joint Infection Diagnosis
Flurin, Laure , Hemenway, Joseph J., Fisher, Cody R. , Vaillant, James J. , Azad, Marisa Ann , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Azad, Marisa , Wolf, Matthew J, Patel, Robin , Fisher, Cody , Wolf, Matthew J., Abdel, Matthew P.

Mayo Clinic

mBio | November 10, 2022 | Volume: 13 | Issue: 6 | Pages: No page available

10.1128/mbio.01322-22 | PMID 36354331 Get It

Periprosthetic joint infection (PJI) is a dreadful complication of joint replacement. Noninvasive identification of infectious pathogens has been traditionnally limited to culture-based testing of synovial fluid which has poor sensitivity.
Author response: A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
Yan, Jianhua , Li, Hongsong , Jiao, Kunli , Yang, Jingchun , Port, Jenna , Wang, Jun , Li, Yi‐Gang , Ding, Yonghe , Lang, Di , Bu, Haisong , Ni, Haibo , Morotti, Stefano , Le, Tai , Clark, Karl J. , Ekker, Stephen C. , Cao, Hung , Zhang, Yuji , Grandi, Eleonora , Li, Zhiqiang , Shi, Yongyong , Glukhov, Alexey V. , Xu, Xiaolei

Mayo Clinic

No container title available | November 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.77327.sa2 Get It

Antibiofilm Activity of a Tunable Hypochlorous Acid‐Generating Electrochemical Bandage Controlled by a Wearable Potentiostat
Raval, Yash S. , Gelston, Suzanne , Tibbits, Gretchen , Flurin, Laure , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Beyenal, Haluk , Patel, Robin , Beyenal, H , Greenwood-Quaintance, Kerryl , Raval, Yash S. , Mohamed, Abdelrhman , Ay, Suat Utku

Mayo Clinic

Advanced Engineering Materials | October 26, 2022 | Volume: 25 | Issue: 1 | Pages: No page available

10.1002/adem.202200792 | PMID 36817722 Get It

Chronic wound biofilm infections represent a major clinical challenge which results in a substantial burden to patients and healthcare systems. Treatment with topical antibiotics is oftentimes ineffective as a result of antibiotic‐resistant microorganisms and biofilm‐specific antibiotic tolerance. Use of biocides such as hypochlorous acid (HOCl) has gained increasing attention due to the lack of known resistance mechanisms. An HOCl‐generating electrochemical bandage (e‐bandage) is designed that delivers HOCl continuously at low concentrations targeting infected wound beds in a similar manner to adhesive antimicrobial wound dressings. A battery‐operated wearable potentiostat is developed that controls the e‐bandage electrodes at potentials suitable for HOCl generation. It is demonstrated that e‐bandage treatment is tunable by changing the applied potential. HOCl generation on electrode surfaces is verified using microelectrodes. The developed e‐bandage shows time‐dependent responses against in vitro Acinetobacter baumannii and Staphylococcus aureus biofilms, reducing viable cells to nondetectable levels within 6 and 12 h of treatment, respectively. The developed e‐bandage should be further evaluated as an alternative to topical antibiotics to treat wound biofilm infections.
Exploring Gene Expression Profiles in Primary Central Nervous System Vasculitis
Hunder, Gene G. , Ansell, Stephen M. , Parisi, Joseph E., Croci, Stefania , Brown, Robert D. , Salvarani, Carlo , Paludo, Jonas , Giannini, Caterina , Huston, John , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Annals of Neurology | October 20, 2022 | Volume: 93 | Issue: 1 | Pages: 120-130

10.1002/ana.26537 | PMID 36264136 Get It

ObjectiveThis study was undertaken to explore the gene expression profile of primary central nervous system vasculitis (PCNSV).MethodsBrain specimens of 4 patients with granulomatous vasculitis (GV), 5 with lymphocytic vasculitis (LV), 4 with amyloid β‐related angiitis (ABRA), and 4 normal controls were studied. RNA‐sequencing was performed using the Illumina Hiseq‐4,000 platform and the Illumina TruSeq Total‐RNA library. Student t test and false discovery rate tests were performed for each of the differentially expressed transcripts. Ingenuity Pathway Analysis was used for the pathway expression analysis. CIBERSORT was used to estimate the abundances of different immune cell subsets in the tissues based on gene expression data.ResultsTranscripts differentially expressed between PCNSV and normal brain indicated that endosomal, mitochondrial, and ribosome dysfunction, alterations in protein synthesis, and noncoding RNAs might be involved in PCNSV. Pathway analysis revealed the activation of dendritic cell maturation and antigen processing as well as neuroinflammation in PCNSV versus normal brain, whereas oxidative phosphorylation was inhibited. CIBERSORT estimation of immune cell subsets suggested that activated NK cells, M1 macrophages, memory B cells, and follicular helper T cells were likely to be more prevalent in PCNSV samples. Naïve CD4 T cells and monocytes were mainly estimated to be present in GV and ABRA. Plasma cell and γδ T‐cell signatures were mainly found in LV and normal brain. GV showed higher levels of genes associated with macrophage activities and T cells. ABRA showed higher levels of long noncoding RNAs and miR‐616. LV showed higher levels of genes encoding immunoglobulins.InterpretationRNA sequencing confirmed PCNSV heterogeneity. ANN NEUROL 2023;93:120–130
Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
Moghe, Manish , Rait, Antonina, Pirollo, Kathleen F., Harford, Joe B. , Chang, Esther H. , Doherty, Caroline , Moghe, Manish , Kim, Sang Soo , Doherty, Caroline Lloyd

Mayo Clinic

Cancers | October 18, 2022 | Volume: 14 | Issue: 20 | Pages: 5092

10.3390/cancers14205092 | PMID 36291878 Get It

Because lung cancer remains the most common and lethal of cancers, novel therapeutic approaches are urgently needed. RB94 is a truncated form of retinoblastoma tumor suppressor protein with elevated anti-tumor efficacy. Our investigational nanomedicine (termed scL-RB94) is a tumor-targeted liposomal formulation of a plasmid containing the gene encoding RB94. In this research, we studied anti-tumor and immune modulation activities of scL-RB94 nanocomplex in preclinical models of human non-small cell lung cancer (NSCLC). Systemic treatment with scL-RB94 of mice bearing human NSCLC tumors significantly inhibited tumor growth by lowering proliferation and increasing apoptosis of tumor cells in vivo. scL-RB94 treatment also boosted anti-tumor immune responses by upregulating immune recognition molecules and recruiting innate immune cells such as natural killer (NK) cells. Antibody-mediated depletion of NK cells blunted the anti-tumor activity of scL-RB94, suggesting that NK cells were crucial for the observed anti-tumor activity in these xenograft models. Treatment with scL-RB94 also altered the polarization of tumor-associated macrophages by reducing immune-suppressive M2 macrophages to lower immune suppression in the tumor microenvironment. Collectively, our data suggest that the efficacy of scL-RB94 against NSCLC is due to an induction of tumor cell death as well as enhancement of innate anti-tumor immunity.
A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
Ding, Yonghe , Yan, Jianhua , Li, Hongsong , Jiao, Kunli , Yang, Jingchun , Port, Jenna , Wang, Jun , Shi, Yongyong , Li, Yi‐Gang , Bu, Haisong, Clark, Karl J , Ekker, Stephen C , Lin, Xueying , Ding, Yonghe , Lang, Di , Bu, Haisong , Ni, Haibo , Morotti, Stefano , Le, Tai , Clark, Karl J. , Ekker, Stephen C. , Cao, Hung , Zhang, Yuji , Grandi, Eleonora , Li, Zhiqiang , Glukhov, Alexey V. , Xu, Xiaolei

Mayo Clinic

eLife | October 18, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.77327 | PMID 36255053 Get It

Previously we showed the generation of a protein trap library made with the gene-break transposon (GBT) in zebrafish ( Danio rerio ) that could be used to facilitate novel functional genome annotation towards understanding molecular underpinnings of human diseases (Ichino et al, 2020). Here, we report a significant application of this library for discovering essential genes for heart rhythm disorders such as sick sinus syndrome (SSS). SSS is a group of heart rhythm disorders caused by malfunction of the sinus node, the heart’s primary pacemaker. Partially owing to its aging-associated phenotypic manifestation and low expressivity, molecular mechanisms of SSS remain difficult to decipher. From 609 GBT lines screened, we generated a collection of 35 zebrafish insertional cardiac (ZIC) mutants in which each mutant traps a gene with cardiac expression. We further employed electrocardiographic measurements to screen these 35 ZIC lines and identified three GBT mutants with SSS-like phenotypes. More detailed functional studies on one of the arrhythmogenic mutants, GBT411 , in both zebrafish and mouse models unveiled Dnajb6 as a novel SSS causative gene with a unique expression pattern within the subpopulation of sinus node pacemaker cells that partially overlaps with the expression of hyperpolarization activated cyclic nucleotide gated channel 4 (HCN4), supporting heterogeneity of the cardiac pacemaker cells.
Acute myocarditis associated with desmosomal gene variants
Raimondi, F, Olivotto, Iacopo, Peretto, G, Merlo, M, Camici, P G, Ammirati, Enrico , Piriou, Nicolas , Mohiddin, Saidi , Imazio, Massimo , Aquaro, Giovanni Donato , Olivotto, Iacopo , Heyning, Caroline M. Van De , Merlo, M, Klaassen, Sabine , Poller, Wolfgang , Adler, Eric D , Cooper, Leslie T.

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.1682 Get It

Abstract Background The risk of adverse cardiovascular events in patients with acute myocarditis (AM) and desmosomal gene variants (DGV) remains unknown. Purpose To ascertain the risk of death, ventricular arrhythmias, recurrent myocarditis, and heart failure (main endpoint) in patients with AM and pathogenic or likely pathogenetic DGV. Methods In a retrospective international study from 23 hospitals, 97 patients were included: 36 with AM and DGV (DGV(+)), 25 with AM and negative gene testing (DGV(−)), and 36 AM patients without genetics (w/o genetics). All patients had troponin elevation plus findings consistent with AM on histology or at cardiac magnetic resonance imaging (CMRI). In 86 patients CMRI changes in function and structure were re-assessed at follow-up. Results In the DGV(+) AM group (88.9% DSP variants), median age was 24 years, 91.7% presented with chest pain, and median left ventricular (LV) ejection fraction was 56% on CMRI (p=NS vs. the other 2 groups). Kaplan-Meier curves demonstrated a higher risk of the main endpoint in DGV(+) AM compared to DGV(−) and w/o genetics patients (62.3% vs. 17.5% vs. 5.3% at 5 years respectively; p<0.0001), driven by myocarditis recurrence and ventricular arrhythmias (Figure 1A, B). At follow-up CMRI, a higher number of late-gadolinium enhanced segments was found in DGV(+) AM. Conclusions Patients with AM and evidence of DGV have a higher incidence of adverse cardiovascular events compared with AM patients without DGV. Further prospective studies are needed to ascertain if genetic testing might improve risk stratification of patients with AM who are considered at low risk. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Italian Ministry of Health
Transformation of FL into DLBCL with a PMBL gene expression signature
Loveday, Tristan , Duns, Gerben , Rimsza, Lisa M. , Rech, Karen L. , Cook, James R. , Robetorye, Ryan S. , Ramsower, Colleen , Yip, Tameson, McKinney, Catherine L., Bhavsar, Shweta , Rosenthal, Allison , Ramsower, Colleen A , Yip, Tameson K, Swerdlow, Steven H , Bhavsar, Shweta , Steidl, Christian , Gibson, Sarah E , Rimsza, Lisa M , Rech, Karen , Mckinney, Catherine, Swerdlow, Steven H. , Steidl, Christian , Gibson, Sarah E.

Mayo Clinic

Blood Advances | October 14, 2022 | Volume: 7 | Issue: 6 | Pages: 893-899

10.1182/bloodadvances.2022007360 | PMID 36240289 Get It

Abstract We investigated the clinicopathologic features of 5 follicular lymphomas (FLs) that transformed (tFL) morphologically to diffuse large B-cell lymphomas (DLBCLs) and had a primary mediastinal large B-cell lymphoma (PMBL)–like gene expression profile (tFL-PMBLsig-pos). None of the tFL-PMBLsig-pos cases arose in the mediastinum, all cases tested had a germinal center B-cell phenotype, 20% were CD30+, 60% CD23+, 80% MAL+, 20% CD200+, and 0% CD273/PDL2+. Whole-exome sequencing detected alterations in genes associated with both FL/DLBCL (CREBBP, KMT2C, KMT2D, ARID1A, HIST1 members, and TNFRSF14) and PMBL (JAK-STAT pathway genes, B2M, and CD58). Copy number (CN) analysis detected gains/amplification of REL and STAT6 in 60%, gains of SOCS1 in 40%, and gains of chromosome 16, including IL4R, in 40% of the cases. CN gains/amplification of BCL6 and MYC and loss of TNFRSF14 and TNFAIP3 were identified in 20% of the cases. Three of 5 cases lacked a BCL2 rearrangement. Despite having some features that are less common in DLBCL (MAL and CD23 expression and JAK-STAT activation), these tFL-PMBLsig-pos cases lack the most characteristic CN alteration seen in PMBL (9p24.1 gain/amplification). This cohort expands the biologic heterogeneity of tFL, illustrating a subset with gene expression and some genetic features reminiscent of PMBL, with potential treatment implications that include the use of novel targeted therapies.
Suppression and Replacement Gene Therapy for KCNH2 -Mediated Arrhythmias
Bains, Sahej , Zhou, Wei , Dotzler, Steven M. , Martinez, Katherine , Kim, CS John, Tester, David J. , Ye, Dan , Ackerman, Michael J. , Bains, Sahej , Ye, Dan

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 13, 2022 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/circgen.122.003719 | PMID 36252106 Get It

Background: KCNH2 -mediated arrhythmia syndromes are caused by loss-of-function (type 2 long QT syndrome [LQT2]) or gain-of-function (type 1 short QT syndrome [SQT1]) pathogenic variants in the KCNH2 -encoded K v 11.1 potassium channel, which is essential for the cardiac action potential. Methods: A dual-component “suppression-and-replacement” (SupRep) KCNH2 gene therapy was created by cloning into a single construct a custom-designed KCNH2 short hairpin RNA with ~80% knockdown (suppression) and a “short hairpin RNA-immune” KCNH2 cDNA (replacement). Induced pluripotent stem cell-derived cardiomyocytes and their CRISPR-Cas9 variant-corrected isogenic control (IC) induced pluripotent stem cell-derived cardiomyocytes were made for 2 LQT2- (G604S, N633S) and 1 SQT1- (N588K) causative variants. All variant lines were treated with KCNH2-SupRep or non-targeting control short hairpin RNA (shCT). The action potential duration (APD) at 90% repolarization (APD 90 ) was measured using FluoVolt voltage dye. Results: KCNH2-SupRep achieved variant-independent rescue of both pathologic phenotypes. For LQT2-causative variants, treatment with KCNH2-SupRep resulted in shortening of the pathologically prolonged APD 90 to near curative (IC-like) APD 90 levels (G604S IC, 471±25 ms; N633S IC, 405±55 ms) compared with treatment with shCT (G604S: SupRep-treated, 452±76 ms versus shCT-treated, 550±41 ms; P <0.0001; N633S: SupRep-treated, 399±105 ms versus shCT-treated, 577±39 ms, P <0.0001). Conversely, for the SQT1-causative variant, N588K, treatment with KCNH2-SupRep resulted in therapeutic prolongation of the pathologically shortened APD 90 (IC: 429±16 ms; SupRep-treated: 396±61 ms; shCT-treated: 274±12 ms). Conclusions: We provide the first proof-of-principle gene therapy for correction of both LQT2 and SQT1. KCNH2-SupRep gene therapy successfully normalized the pathologic APD 90 , thereby eliminating the pathognomonic feature of both LQT2 and SQT1.
Faculty Opinions recommendation of Directed evolution of adeno-associated virus for efficient gene delivery to microglia.
Bosco, Dale B. , Wu, Long‐Jun

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 10, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742251078.793595809 Get It